Snapshot COVID-19 data - Information for these slides is from public sources. IFPMA is not involved in the collection of this data.
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
Snapshot COVID-19 data Science, trial forecast, production and news analysis December 8, 2020 Information for these slides is from public sources. IFPMA is not involved in the collection of this data. © 2020 Airfinity Ltd | Private & Confidential.
Daily infections per 10,000 people and testing capacity per capita
Infection trajectory Daily tests per capita
Last Current Forecasted 1 15
week
© 2020 Airfinity Ltd | Private &
2
Confidential
Calculated using data from Our World in DataAnalysis of candidates being trialled for the treatment of COVID-19
Number of treatments in investigation Clinical trials by stage of intervention
1 138
920
Number of treatments
Number of clinical trials for COVID-19 426
treatment 354
2
2,212 202
149
113
1 032
529 29 19
Healthy Prevention Mild Moderate Severe Critical Rehabilitation Unknown
Number of Average Average Volunteer
clinical trials for number of number of s
COVID-19 participants in participants in
treatments clinical trials phase III trials
© 2020 Airfinity Ltd | Private &
3
ConfidentialOverview of treatments currently being used in a clinical setting
Disease severity (Evidence in each indication)
Type of treatment Candidate/Intervention
Mild Moderate Severe/Critical
Interferon Beta-1A
Interferon Beta-1A
Anti-inflammatory or
Anti-inflammatory
immunomodulatoror InterferonBeta-1A
Beta-1A (Nebulised)
(Nebulised)
Interferon
immunomodulator
Hydroxychloroquine
Hydroxychloroquine
Remdesivir
Remdesivir
Favipiravir
Favipiravir
Antiviral
Antiviral Lopinavir with
Lopinavir with Ritonavir
Ritonavir
Camostat Mesylate
Camostat Mesylate
Umifenovir
Umifenovir
Methylprednisolone
Methylprednisolone
Steroid
Steroid Dexamethasone
Dexamethasone
Baricitinib(and
Baricitinib (andRemdesivir)
Remdesivir)
Antibody (anti-
Antibody (anti- Tocilizumab
inflammatory) Tocilizumab
inflammatory)
Other
Other Aviptadil
Aviptadil
Antithrombotic Enoxaparin
Enoxaparin
Antithrombotic
Heparin
Heparin
Antibody (passive Regn-CoV2 (Regeneron/Roche)
Regn-CoV2 (Regeneron/Roche)
Antibody (passive
immunotherapy) Bamlanivimab
Bamlanivimab (LyCov555)
(LyCov555)
immunotherapy)
Convalescent
Convalescent Plasma
Plasma
Standard of care varies from trial to trial, but is
Better than SOC Equal to SOC
considered to be the standard protocol of treatment © 2020 Airfinity Ltd | Private &
4
of a patient at that stage of disease severity. Rejected/Worse than SOC No/insufficient data ConfidentialOverview of the vaccine candidates
Total number of COVID-19 vaccine candidates Vaccines by vaccine type
347 2%
14%
21% Whole virus
Protein subunit
DNA/mRNA
Viral vector
23% 40%
Unknown
Total number of vaccines
Average number participants in phase III clinical
Total doses committed in deals so far
trials
10 932 180 000 15 083
Doses committed so far Average number of participants
in phase III COVID-19 vaccine
trials
© 2020 Airfinity Ltd | Private &
5
ConfidentialAnalysis of potential readouts of phase III vaccine trials
Vaccine 2020 2021
(# Q4 Q1
participants) Oct Nov Dec Jan Feb
AZN (20,260)
22.11.2020 05.12.2020
USA (30,000)
30.01.2021 22.02.2021
Pfizer
(44,000)
/BioNTech 03.10.2020 18.10.2020 02.11.2020 14.11.2020 21.11.2020 03.12.2020
Moderna (30,000)
24.10.2020 13.11.2020 22.11.2020 29.11.2020
(60,000)
J&J (30,000)
28.01.2021 06.02.2021
19.02.2021
(15,000)
NVX 07.02.2021 19.02.2021
(30,000)
04.02.2021 19.02.2021
Sputnik-V(40,000)
09.11.2020 22.11.2020 09.12.2020 01.01.2021 21.02.2021
SinoVac (11,790)
26.10.2020 25.11.2020 04.01.2021
(40,000)
CanSino
(15,000) 27.11.2020 06.12.2020
(45,000) 13.02.2021
Sinopharm(3,000) 27.10.2020 01.11.2020 02.01.2021
(6,000) 21.01.2021 19.02.2021 19.02.2021
03.12.2020 22.01.2021
© 2020 Airfinity Ltd | Private &
6
Confidential
Estimated interim analysis readout from first to fourth Estimated primary endpoint readout Estimated time to 150 confirmed Estimated 2 month safetyOverview of second generation COVID-19 vaccines
Second generation COVID-19 vaccines
Candidate Phase III start
Sanofi/GSK vaccine End of 2020
287 CureVac vaccine Q4 2020
Themis/Merck candidate End of 2020
Uni. of Queensland
Dec 2020
candidate
ZyCoV-D (Zydus Cadila) Dec 2020
Inactivated virus(Chinese
Nov/Dec 2020
academy of MS)
Recombinant protein (Zhifei) Dec 2020
VLP (Medicago) Dec 2020
23
17 12
7
1
Preclinical Phase I Phase I/II Phase II Phase II/III Phase III
© 2020 Airfinity Ltd | Private &
Candidates 7
ConfidentialExpected vaccine production by end of 2021
United States 2,776,000,000
India 2,750,000,000
China 1,800,000,000
France 1 000 000 000
United Kingdom 661,000,000
Czech Republic 500 000 000
Switzerland 450,000,000
Netherlands 400,000,000
Belgium 325 000 000 Vaccine (Valneva)
Vaccine (Zydus Cadila)
Argentina 250 000 000
Vaccine (Medicago)
Japan 250 000 000 CVnCoV (Curevac)
Sputnik-V
Brazil 200 000 000
CanSino
Germany 200 000 000 CoronaVac (Sinovac)
Sinopharm candidates
South Korea 200 000 000
mRNA-1273 (Moderna)
Spain 150 000 000 Ad26COVS1 (J&J)
mRNA-BNT162 (Pfizer/BioNTech)
Canada 100 000 000
Vaccine (Sanofi/GSK)
Russia 63 500 000 NVX-CoV2373 (Novavax)
AZD1222 (AstraZeneca)
Australia 30 000 000
© 2020 Airfinity Ltd | Private &
8
Confidential
Italy 13,000Back to normal immunization forecasts
Timeline for countries/regions to reach herd immunity based on agreed vaccine supply deals
Immunity forecast
2021 2022 2023
Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1
United States
22.02.202124.04.2021
United Kingdom
09.04.2021 10.07.2021
Canada
01.04.202109.06.2021
European Union
09.05.2021 02.09.2021
Australia
01.07.2021 08.12.2021
Japan
15.10.2021 08.04.2022
Latin America
26.06.2021 26.03.2022
India
25.02.2023
China
30.06.2021 02.10.2022
Russia
15.11.2021
Healthcare and high-risk Herd immunity estimate, based on current
20% population immunised population immunised supply deals, with domestic production
supplied first © 2020 Airfinity Ltd | Private &
9
ConfidentialCopyright notice All intellectual property rights in this publication and the information published herein are the exclusive property of Airfinity and may only be used under licence from Airfinity. Without limiting the foregoing, by accessing this publication you agree that you will not copy or reproduce or recirculate or distribute or use any part of its contents in any form or for any purpose whatsoever except under valid licence from Airfinity. Unauthorised distribution is strictly prohibited. Disclaimer The data and other information published herein are provided on an "as is basis". Airfinity makes no warranties, express or implied, as to the accuracy, adequacy, timeliness, or completeness of the data or fitness for any particular purpose. Airfinity shall not be liable for any loss, claims or damage arising from any party's reliance on the data and disclaim any and all liability relating to or arising out of use of the data to the full extent permissible by law. For more information: Rasmus Bech Hansen, CEO rasmus@airfinity.com Copyright © 2020 Airfinity Ltd | All Rights Reserved | Private & Confidential
You can also read
